Ovid Therapeutics Inc. is a privately held, New York-based, biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain. Ovid focuses on patients and their unmet medical needs. Using the significant operational, product development and business development experience of its management team, Ovid aims to become a leading neurology company, with multiple products and a rich pipeline, coupled with compelling research and development.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/11/15 | $75,000,000 | Series B |
Cormorant Asset Management Cowen Private Investments DoubleLine Equity Healthcare Fund Fidelity Management & Research Company Jennison Associates Redmile Group Sanofi-Genzyme BioVentures Sphera Global Healthcare Tekla Capital Management | undisclosed |
